Mitsubishi UFJ Trust & Banking Corp decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 194,480 shares of the medical device company’s stock after selling 9,140 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.22% of DexCom worth $27,818,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Waddell & Reed Financial Inc. lifted its holdings in DexCom by 164.8% in the second quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock worth $54,075,000 after purchasing an additional 354,331 shares during the period. Swiss National Bank lifted its holdings in DexCom by 1.0% in the third quarter. Swiss National Bank now owns 153,600 shares of the medical device company’s stock worth $21,971,000 after purchasing an additional 1,500 shares during the period. BlackRock Inc. lifted its holdings in DexCom by 5.9% in the second quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock worth $390,978,000 after purchasing an additional 228,933 shares during the period. Macquarie Group Ltd. lifted its holdings in DexCom by 14.4% in the second quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock worth $22,448,000 after purchasing an additional 29,825 shares during the period. Finally, Federated Investors Inc. PA lifted its holdings in DexCom by 97.1% in the second quarter. Federated Investors Inc. PA now owns 460,209 shares of the medical device company’s stock worth $43,710,000 after purchasing an additional 226,740 shares during the period. 99.05% of the stock is owned by institutional investors.
In other DexCom news, EVP Donald Abbey sold 10,550 shares of the company’s stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $149.30, for a total transaction of $1,575,115.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Patrick Michael Murphy sold 2,372 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $143.69, for a total value of $340,832.68. The disclosure for this sale can be found here. Insiders sold 149,745 shares of company stock worth $21,210,998 in the last 90 days. 1.80% of the stock is currently owned by corporate insiders.
Shares of DXCM traded down $3.74 during trading hours on Thursday, reaching $124.17. The company’s stock had a trading volume of 530,135 shares, compared to its average volume of 2,181,216. The company has a market capitalization of $11.36 billion, a price-to-earnings ratio of -214.09 and a beta of 0.55. DexCom, Inc. has a 1-year low of $51.04 and a 1-year high of $152.14. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43.
DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.29. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. The company had revenue of $266.70 million for the quarter, compared to the consensus estimate of $242.72 million. The business’s quarterly revenue was up 44.5% compared to the same quarter last year. Equities research analysts expect that DexCom, Inc. will post -0.12 earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on DXCM shares. Northland Securities raised shares of DexCom from an “under perform” rating to a “market perform” rating in a report on Wednesday, September 12th. Goldman Sachs Group raised shares of DexCom from a “sell” rating to a “neutral” rating and set a $125.00 price target for the company in a report on Friday, October 19th. Stephens upped their price target on shares of DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a report on Thursday, August 23rd. Canaccord Genuity upped their price target on shares of DexCom from $125.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, August 23rd. Finally, BidaskClub raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 21st. Nine research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $132.65.
TRADEMARK VIOLATION NOTICE: This article was originally reported by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.fairfieldcurrent.com/news/2018/12/06/mitsubishi-ufj-trust-banking-corp-decreases-holdings-in-dexcom-inc-dxcm.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: Outstanding Shares
Receive News & Ratings for DexCom Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom and related companies with MarketBeat.com’s FREE daily email newsletter.